Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais
Accueil / Enregistré au Nigeria / Bafnacare 200 mg Tablets

Bafnacare 200 mg Tablets

NAFDAC REG NO: A4-101201 Médicament

Enregistré auprès de NAFDAC. Enregistrement actifAs of 29 October 2026 · synced automatically from official sources.
Produit
Bafnacare 200 mg Tablets
Numéro NAFDAC
A4-101201
Principe actif
Aciclovir
Dosage
200 mg
Forme
Tablet
Conditionnement
5 x 5's ( in Alu-PVC blisters)
Fabricant
Non répertorié
Déposant / Titulaire :
AnnyGod Pharmaceutical Company Ltd
Approuvé
28 Feb 2025
Statut
Actif Vue sur NAFDAC ↗
Enregistrement valable jusqu'au
27 Feb 2030
Alertes OMS
Non trouvé
Community reports
None
Times checked
0

About the medicine: Aciclovir: uses, dosage and brands worldwide

What we found

  • Bafnacare 200 mg Tablets is on the NAFDAC register with an active registration (A4-101201). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Bafnacare 200 mg Tablets

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Pour qui

Herpes Zoster Infections : Acyclovir is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes : Acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox : Acyclovir is indicated for the treatment of chickenpox (varicella).

Comment le prendre et à quelle fréquence
  • Acute Treatment of Herpes Zoster : 800 mg every 4 hours orally, 5 times daily for 7 to 10 days
  • Genital Herpes : Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days
  • Chronic Suppressive Therapy for Recurrent Disease: 400 mg 2 times daily for up to 12 months, followed by re-evaluation
  • Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily
  • The frequency and severity of episodes of untreated genital herpes may change over time
  • After 1 year of therapy, the frequency and severity of the patient's genital herpes infection should be re-evaluated to assess the need for continuation of therapy with acyclovir
  • Intermittent Therapy: 200 mg every 4 hours, 5 times daily for 5 days
  • Therapy should be initiated at the earliest sign or symptom (prodrome) of recurrence
  • Treatment of Chickenpox : Children (2 years of age and older): 20 mg/kg per dose orally 4 times daily (80 mg/kg/day) for 5 days
  • Children over 40 kg should receive the adult dose for chickenpox
  • Adults and Children over 40 kg: 800 mg 4 times daily for 5 days
  • Intravenous acyclovir is indicated
  • For the treatment of varicella-zoster infections in immunocompromised patients
  • When therapy is indicated, it should be initiated at the earliest sign or symptom of chickenpox
Children
  • Safety and effectiveness of oral formulations of acyclovir
  • In pediatric patients younger than 2 years of age have not been established
Older adults

Of 376 subjects who received acyclovir in a clinical study of herpes zoster treatment in immunocompetent subjects ≥50 years of age, 244 were 65 and over while 111 were 75 and over. No overall differences in effectiveness for time to cessation of new lesion formation or time to healing were reported between geriatric subjects and younger adult subjects. The duration of pain after healing was longer in patients 65 and over. …

While you are taking it
  • Patients are instructed to consult with their physician if they experience severe or troublesome adverse reactions, they become pregnant or intend to become pregnant, they intend to breast feed while taking orally administered acyclovir, or they have any other questions
  • Patients should be advised to maintain adequate hydration
  • Herpes Zoster : There are no data on treatment initiated more than 72 hours after onset of the zoster rash
  • Patients should be advised to initiate treatment as soon as possible after a diagnosis of herpes zoster
  • Genital Herpes Infections: Patients should be informed that acyclovir is not a cure for genital herpes. …
Talk to a doctor first if

Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

Medicines it may not mix with

See CLINICAL PHARMACOLOGY: Pharmacokinetics .

Warnings

Acyclovir capsules are intended for oral ingestion only. Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS: Observed During Clinical Practice and OVERDOSAGE ). Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy.

Effets secondaires possibles

Herpes Simplex: Short-Term Administration: The most frequent adverse events reported during clinical trials of treatment of genital herpes with acyclovir 200 mg administered orally 5 times daily every 4 hours for 10 days were nausea and/or vomiting in 8 of 298 patient treatments (2.7%). Nausea and/or vomiting occurred in 2 of 287 (0.7%) patients who received placebo. Long-Term Administration: The most frequent adverse events reported in a clinical trial for the prevention of recurrences with continuous administration of 400 mg (two 200-mg capsules) 2 times daily for 1 year in 586 patients treated with acyclovir were nausea (4.8%) and diarrhea (2.4%). …

Pregnancy and breastfeeding

Pregnancy: Teratogenic Effects: Pregnancy Category B. Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, p.o.), rabbit (50 mg/kg/day, s.c. and IV), or rat (50 mg/kg/day, s.c.). These exposures resulted in plasma levels 9 and 18, 16 and 106, and 11 and 22 times, respectively, human levels. There are no adequate and well-controlled studies in pregnant women. …

If you take too much

Overdoses involving ingestion of up to 100 capsules (20 g) have been reported. Adverse events that have been reported in association with overdosage include agitation, coma, seizures, and lethargy. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Overdosage has been reported following bolus injections or inappropriately high doses and in patients whose fluid and electrolyte balance were not properly monitored. This has resulted in elevated BUN and serum creatinine and subsequent renal failure. …

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-09-05.

Label for aciclovir, the active ingredient registered with NAFDAC.

Check your pack of Bafnacare 200 mg Tablets

Add the expiry date on your pack for a full Trust Score.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Sources officielles : FDA américaine · EMA (UE) · NAFDAC · alertes OMS

About Bafnacare 200 mg Tablets

What is in Bafnacare 200 mg Tablets?

Bafnacare 200 mg Tablets contains Aciclovir (200 mg), as tablet, according to its NAFDAC registration record.

Is Bafnacare 200 mg Tablets registered with NAFDAC?

Yes. Bafnacare 200 mg Tablets is listed on the NAFDAC register under registration number A4-101201, and its registration is active as of 29 October 2026.

Has Bafnacare 200 mg Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Bafnacare 200 mg Tablets in our automatically synced alert list.

How can I check that my pack of Bafnacare 200 mg Tablets is genuine?

Run a free authenticity scan with the NAFDAC number A4-101201, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Bafnacare 200 mg Tablets?

Follow your prescription or the leaflet in your pack. The official label says: Acute Treatment of Herpes Zoster : 800 mg every 4 hours orally, 5 times daily for 7 to 10 days. Genital Herpes : Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days. Chronic Suppressive Therapy for Recurrent Disease: 400 mg 2 times daily for up to 12 months, followed by re-evaluation. Alternative regimens have included doses ranging from 200 mg …

What is Bafnacare 200 mg Tablets used for?

Herpes Zoster Infections : Acyclovir is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes : Acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox : Acyclovir is indicated for the treatment of chickenpox (varicella). (Summarised from the official U.S. FDA label for aciclovir. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Bafnacare 200 mg Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.